摘要
目的探讨复发转移性乳腺癌组织中Tau蛋白的表达情况及其与紫杉醇药物姑息性化疗敏感性的相关性。方法采用免疫组化Envision二步法检测136例复发转移性乳腺癌患者转移病灶的组织样本中Tau蛋白的表达水平,χ2检验或Fisher精确概率法分析其与复发转移性乳腺癌临床病理特征及与紫杉醇类药物姑息性化疗敏感性的关系。结果复发转移性乳腺癌患者Tau蛋白的阳性表达率为28.68%(39/136),Tau蛋白的阳性表达与患者的年龄、身体密度、ECOG分值、病理分型、组织学分级、孕激素受体、表皮生长因子受体-2、增殖指数Ki-67及P53阳性表达均无相关性,但与乳腺癌组织的雌激素受体表达相关(P<0.05)。而且,Tau蛋白的表达与紫杉醇药物性化疗疗效相关(P<0.01)。结论 Tau蛋白表达水平与复发转移性乳腺癌紫杉醇类药物姑息性化疗敏感性呈负相关,临床检测Tau蛋白表达可能可作为复发转移性乳腺癌行紫杉醇类药物性姑息性化疗方案的选择依据。
ObjectiveTo investigate the expression of Tau protein in recurrent and metastatic breast cancer and the correlation between Tau protein and the effect of taxane-containing palliative chemotherapy. MethodsThe expression of Tao protein in the metastatic breast tumor tissue of 136 patients with recurrent and metastatic breast cancer was detected by immunohistochemistry.The correlation between the expression of Tao protein and clinical variables, such as taxane sensitivity and the associations between Tau expression and the efficiency of taxane-containing palliative chemotherapy was used by χ2 test or Fisher exact probability test. ResultsThe expression of Tau protein in thirty-nine (28.68%, 39/136) patients was positive. The expression of Tau protein was positively related to ER (P〈0.05) and negatively related with the effect of taxanes-containing palliative chemotherapy (P〈0.01). ConclusionThe expression of Tau protein was negatively related with the effect of taxane-containing palliative chemotherapy. The detection of the expression of Tau protein in recurrent and metastatic breast cancer may be a clinical basis to choose taxane-containing palliative chemotherapy.
出处
《岭南现代临床外科》
2014年第2期153-156,共4页
Lingnan Modern Clinics in Surgery
基金
广州市医药卫生科技项目(编号:20121A011166)
关键词
TAU蛋白
复发转移
乳腺癌
紫杉醇
Tau protein
Recurrent and metastatic
Breast cancer
Taxane